Mortality in people diagnosed with CFS/ME

A 2016 large-scale cohort study by Roberts and colleagues, published in The Lancet, examined mortality outcomes in people diagnosed with CFS/ME in UK primary care. The headline finding — that all-cause mortality was not significantly elevated compared to the general population — has sometimes been used to argue that ME/CFS is not a serious condition. The paper's actual data argue the opposite. The absence of elevated all-cause mortality, read alongside the significantly elevated suicide risk, tells a specific and uncomfortable story about what ME/CFS does to people's lives — and what the healthcare system's response to the condition is contributing to those outcomes.

The Cohort and the Methodology

Roberts and colleagues used UK Clinical Practice Research Datalink data to identify patients with a recorded CFS/ME diagnosis and follow them over time. The cohort included over 2,000 patients diagnosed in primary care between 2002 and 2011. They were matched to age- and sex-comparable controls from the general population. Mortality outcomes were assessed across all causes and across specific cause-of-death categories, with standardized mortality ratios calculated to compare observed deaths in the CFS cohort to expected deaths based on matched population rates.

The UK primary care setting is significant context. Patients receiving a CFS/ME diagnosis in UK primary care during this period were doing so in a healthcare environment that had formally endorsed graded exercise therapy and cognitive behavioral therapy as primary treatments — interventions that a substantial number of patients reported worsening their condition — and where neurological or autonomic mechanisms were not typically part of the clinical investigation.

All-Cause Mortality: What the Data Show and What They Do Not

The overall finding was that people with ME/CFS did not have significantly elevated all-cause mortality compared to matched controls. On the specific measure of dying sooner from any cause, the CFS cohort did not differ substantially from the general population. Cancer mortality was not elevated. Cardiovascular mortality was not elevated. Respiratory mortality was not elevated.

This finding has been cited as evidence that ME/CFS is not a medically serious condition — the reasoning being that serious conditions kill people and this one apparently does not. This interpretation makes two errors. First, not dying sooner is not the same as being well. Severe disability that does not produce early death is still severe disability. People with ME/CFS are not dying from the condition in disproportionate numbers, but many are spending years or decades with profound functional impairment, cognitive disability, and inability to work, maintain relationships, or perform basic activities of daily life. The absence of early death does not address any of that.

Second: the data do contain an elevated mortality signal. It is in the suicide category.

The Suicide Finding: What Elevated Risk Means in Context

The CFS cohort showed significantly elevated suicide risk compared to both the matched control population and the general population baseline. This is not a marginal finding. Suicide risk at population scale is low, so any statistically significant elevation represents a substantial relative increase in the proportion of people in the cohort who died by suicide.

Roberts and colleagues appropriately declined to over-interpret the mechanism — the study design could not isolate whether this elevation was driven by the condition's direct neurological effects, the social consequences of prolonged severe illness and disbelief, the psychological impact of inadequate clinical management, or some combination. But the directional conclusion is not ambiguous: people with ME/CFS are dying by suicide at a higher rate than comparable people without the diagnosis. The illness is creating conditions that become incompatible with continued life for a subset of the people who have it.

The research on stigma and functional outcomes in ME/CFS provides relevant mechanism. Perceived blame for one's illness, repeated dismissal of legitimate physical symptoms by clinicians, and social isolation from a condition that disrupts employment, relationships, and daily activity over years or decades are risk factors for suicidality. The UK clinical context during the study period — where ME/CFS patients were typically told their symptoms were psychologically mediated and were offered behavioral treatments that many found harmful — is directly relevant to the clinical conditions that patients were experiencing.

The Clinical Minimization Problem This Data Exposes

The "ME/CFS does not kill people" framing has contributed to a clinical culture in which the urgency and severity of the condition are systematically underestimated. Clinicians who might treat a condition with 2% excess mortality with significant concern have used the absence of excess mortality in ME/CFS to justify minimal investigation, brief clinic visits, and management that amounts to reassurance and advice to gradually increase activity.

Roberts et al. 2016 does not change the fact that ME/CFS does not produce elevated cardiovascular or cancer mortality. But it adds the specific finding that it does produce elevated suicide risk — and that finding should change the clinical urgency calculation. A condition that reliably produces years of severe disability, that is systematically disbelieved by the medical community, and that carries a measurable elevated suicide risk is not a low-stakes condition. It is a condition whose stakes have simply been measured on the wrong axes.

What This Research Changes for the Reader

If you have ME/CFS and have been in clinical encounters where your condition was treated as minor because "it doesn't affect lifespan," the Roberts data provide a specific counter-framing. The all-cause mortality finding reflects the statistical outcome of a population — it does not describe the individual experience of prolonged disability, isolation, and inadequate care. The suicide finding tells you what years of those experiences can do to people, and it should tell clinicians what they are contributing to when they dismiss, minimize, or inadequately investigate the condition.

The question this paper raises is not whether ME/CFS kills people. The question it raises is what combination of physiological impairment, inadequate care, and systematic disbelief creates the conditions under which people with ME/CFS die by suicide at elevated rates — and what the medical community's obligations are in response to that finding.